← All trials
NCT01986127
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BarcelonaLead sponsor
- Hospital Son EspasesOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Complexo Hospitalario de SantiagoOverall official - principal investigator
- University AlicanteOverall official - principal investigator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- University of BarcelonaCollaborator
- Complexo Hospitalario Arquitecto MarcideOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- University of BurgosOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.